Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
Descripción del Articulo
Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peru...
| Autores: | , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2018 |
| Institución: | Instituto Nacional de Enfermedades Neoplásicas |
| Repositorio: | INEN-Institucional |
| Lenguaje: | español |
| OAI Identifier: | oai:repositorio.inen.sld.pe:20.500.14703/455 |
| Enlace del recurso: | https: //doi.org/10.17843/rpmesp.2018.351.3599 https://hdl.handle.net/20.500.14703/455 |
| Nivel de acceso: | acceso abierto |
| Materia: | Chemotherapy Cytoreduction surgical procedures Neoadjuvant therapy Ovarian neoplasms Peru https://purl.org/pe-repo/ocde/ford#3.02.21 |
| id |
INEN_de7df0130e1a5b7666d71de08d246947 |
|---|---|
| oai_identifier_str |
oai:repositorio.inen.sld.pe:20.500.14703/455 |
| network_acronym_str |
INEN |
| network_name_str |
INEN-Institucional |
| repository_id_str |
. |
| dc.title.none.fl_str_mv |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| title |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| spellingShingle |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases Alcarraz Molina, Cindy Chemotherapy Cytoreduction surgical procedures Neoadjuvant therapy Ovarian neoplasms Peru https://purl.org/pe-repo/ocde/ford#3.02.21 |
| title_short |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| title_full |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| title_fullStr |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| title_full_unstemmed |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| title_sort |
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases |
| author |
Alcarraz Molina, Cindy |
| author_facet |
Alcarraz Molina, Cindy Muñiz, Johana Mas, Luis Olivera, Mivael Morante, Zaida |
| author_role |
author |
| author2 |
Muñiz, Johana Mas, Luis Olivera, Mivael Morante, Zaida |
| author2_role |
author author author author |
| dc.contributor.author.fl_str_mv |
Alcarraz Molina, Cindy Muñiz, Johana Mas, Luis Olivera, Mivael Morante, Zaida |
| dc.subject.none.fl_str_mv |
Chemotherapy Cytoreduction surgical procedures Neoadjuvant therapy Ovarian neoplasms Peru |
| topic |
Chemotherapy Cytoreduction surgical procedures Neoadjuvant therapy Ovarian neoplasms Peru https://purl.org/pe-repo/ocde/ford#3.02.21 |
| dc.subject.ocde.none.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.02.21 |
| description |
Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with post-surgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival. |
| publishDate |
2018 |
| dc.date.accessioned.none.fl_str_mv |
2025-08-21T04:22:42Z |
| dc.date.available.none.fl_str_mv |
2025-08-21T04:22:42Z |
| dc.date.issued.fl_str_mv |
2018 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https: //doi.org/10.17843/rpmesp.2018.351.3599 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.14703/455 |
| dc.identifier.journal.none.fl_str_mv |
Revista Peruana de Medicina Experimental y Salud Publica |
| url |
https: //doi.org/10.17843/rpmesp.2018.351.3599 https://hdl.handle.net/20.500.14703/455 |
| identifier_str_mv |
Revista Peruana de Medicina Experimental y Salud Publica |
| dc.language.iso.none.fl_str_mv |
spa |
| language |
spa |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Instituto Nacional de Salud |
| dc.publisher.country.none.fl_str_mv |
PE |
| publisher.none.fl_str_mv |
Instituto Nacional de Salud |
| dc.source.none.fl_str_mv |
reponame:INEN-Institucional instname:Instituto Nacional de Enfermedades Neoplásicas instacron:INEN |
| instname_str |
Instituto Nacional de Enfermedades Neoplásicas |
| instacron_str |
INEN |
| institution |
INEN |
| reponame_str |
INEN-Institucional |
| collection |
INEN-Institucional |
| bitstream.url.fl_str_mv |
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/ff353ba4-5f19-4e12-9011-3161c3512104/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/50eb46b1-6af9-4edd-930a-fe39e33f8dc0/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/4758f7c2-d55d-4423-b924-84ca4b0d03db/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e4c6a931-481b-495a-bec7-82ef51d607af/download |
| bitstream.checksum.fl_str_mv |
3dec5977c31c83b9f09bb076b619657b bb9bdc0b3349e4284e09149f943790b4 01aa4c5f77232e047ccdc2f50272e90e ffbc23babd54dc31c21a67c417dd7dd5 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio del Instituto Nacional de Enfermedades Neoplásicas |
| repository.mail.fl_str_mv |
repositorio@inen.sld.pe |
| _version_ |
1868438552258281472 |
| spelling |
PublicationAlcarraz Molina, CindyMuñiz, JohanaMas, LuisOlivera, MivaelMorante, Zaida2025-08-21T04:22:42Z2025-08-21T04:22:42Z2018https: //doi.org/10.17843/rpmesp.2018.351.3599https://hdl.handle.net/20.500.14703/455Revista Peruana de Medicina Experimental y Salud PublicaObjectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with post-surgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.application/pdfspaInstituto Nacional de SaludPEinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/ChemotherapyCytoreduction surgical proceduresNeoadjuvant therapyOvarian neoplasmsPeruhttps://purl.org/pe-repo/ocde/ford#3.02.21Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseasesinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALadminojs,+8.pdfadminojs,+8.pdfapplication/pdf298906https://repositorio.inen.sld.pe/backend/api/core/bitstreams/ff353ba4-5f19-4e12-9011-3161c3512104/download3dec5977c31c83b9f09bb076b619657bMD51trueAnonymousREADLICENSElicense.txtWritten by org.dspace.content.LicenseUtilstext/plain; charset=utf-81748https://repositorio.inen.sld.pe/backend/api/core/bitstreams/50eb46b1-6af9-4edd-930a-fe39e33f8dc0/downloadbb9bdc0b3349e4284e09149f943790b4MD52falseAnonymousREADTEXTadminojs,+8.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-08-21T08:02:42Z (GMT).Extracted texttext/plain40539https://repositorio.inen.sld.pe/backend/api/core/bitstreams/4758f7c2-d55d-4423-b924-84ca4b0d03db/download01aa4c5f77232e047ccdc2f50272e90eMD53falseAnonymousREADTHUMBNAILadminojs,+8.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-08-21T08:02:43Z (GMT).Generated Thumbnailimage/jpeg44520https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e4c6a931-481b-495a-bec7-82ef51d607af/downloadffbc23babd54dc31c21a67c417dd7dd5MD54falseAnonymousREAD20.500.14703/455oai:repositorio.inen.sld.pe:20.500.14703/4552026-02-17T14:12:01.248Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.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 |
| score |
12.824051 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).